Zevra Therapeutics (ZVRA) Q1 2026 earnings review
Fortress Balance Sheet Achieved, But Core Sales Dip Sequentially
Zevra's Q1 2026 results reflect a masterclass in balance sheet restructuring, though commercial operations flashed a yellow light. The $50M sale of the SDX portfolio allowed the company to completely wipe out its $63.1M term loan, leaving Zevra entirely debt-free with a massive $236.8M cash pile. Operationally, the company reached a major milestone: an estimated adjusted net income of $11.5M, proving the core business can generate cash independent of asset sales. However, top-line quality was mixed. While total net revenue accelerated 78% YoY to $36.2M, it was propped up by a doubling of Global EAP reimbursements. Crucially, U.S. MIPLYFFA product revenue decelerated sequentially, dropping to $24.6M from $26.4M in the prior quarter.
🐂 Bull Case
By divesting the non-core SDX portfolio for $50M and retiring its $63.1M term loan, Zevra eliminated millions in quarterly interest and derivative liability expenses. With $236.8M in cash, the company is fully insulated from capital market volatility.
Excluding the one-time gains and debt extinguishment losses, Zevra generated $11.5M in adjusted net income. This proves the current revenue base is sufficient to support ongoing R&D and SG&A.
🐻 Bear Case
New prescription enrollments dropped to 9 in Q1 (down from 24 in Q4), causing sequential product revenue to contract. If Q4 was a temporary pull-forward rather than a new baseline, U.S. market saturation may be approaching faster than expected.
The Phase 3 DiSCOVER trial for Celiprolol remains sluggish, adding only 10 patients in Q1. With FDA meetings pushed to H2 2026, pipeline catalysts are delayed.
⚖️ Verdict: ⚪
Neutral-to-Bullish. Management executed flawlessly on capital allocation, securing the company's financial future. However, the sequential decline in core commercial sales prevents a higher grade and shifts the burden of proof to next quarter's prescription volumes.
Key Themes
MIPLYFFA's Sequential Deceleration
After a massive Q4 that saw 24 new prescription enrollment forms and $26.4M in product revenue, Q1 returned to earth. The company recorded just 9 new forms, and U.S. MIPLYFFA revenue fell to $24.6M. This suggests that the Q4 spike was anomalous—perhaps a bolus of diagnosed-but-untreated patients—and that the baseline run-rate is closer to the 7-10 range seen in early 2025. Total revenue only beat Q4 because Global EAP reimbursements nearly doubled to $10.2M.
Aggressive and Effective Capital Restructuring
Management orchestrated a brilliant balance sheet cleanup. The $50M sale of the SDX portfolio to Commave Therapeutics provided the exact liquidity needed to wipe out the company's $63.1M term loan. This eliminates roughly $1.7M in quarterly interest expense and removes the volatile derivative liability tied to the debt. Zevra is now an unlevered, cash-generating rare disease platform.
European Expansion Nears Crucial Juncture
The EMA's review of arimoclomol (MIPLYFFA) is advancing, with Zevra submitting its response to the 120-day list of questions. A potential European approval taps into an estimated 1,100 NPC patients. Crucially, Zevra has 122 patients enrolled in its Global EAP (predominantly in Europe), serving as a massive commercial beachhead ready for immediate conversion upon local reimbursement approvals.
DiSCOVER Trial's Agonizing Pace
The Phase 3 DiSCOVER trial for Celiprolol (Vascular Ehlers-Danlos Syndrome) continues to crawl. The company enrolled just 10 patients in Q1, bringing the total to 62. As an event-driven trial (currently at only two confirmed events), this slow enrollment pushes the timeline to data readout significantly to the right. Management is now planning an FDA meeting in H2 2026 to explore 'accelerated pathways,' which is often code for attempting to shrink trial requirements due to feasibility issues.
AI and Technology to Mine Undiagnosed Patients
With the EAP bolus fully converted, Zevra is increasingly reliant on specific technological innovations to find new patients. The company continues to leverage AI-driven data analysis of medical records and claims data, combined with genetic testing partnerships, to identify the 'needle in the haystack'—previously undiagnosed NPC patients. This tech-forward commercial strategy is essential to maintaining growth.
Medicare Part D Macro Headwinds
While not explicitly quantified in the Q1 press release, the rare disease macro environment remains pressured by the Medicare Part D rebate redesign (which shifts more catastrophic phase liability to manufacturers). Zevra suffered a $1.2M gross-to-net true-up in 25Q3 for this exact reason, and variations in payer mix will continue to introduce revenue volatility for MIPLYFFA moving forward.
Other KPIs
Reversing into true operational profitability. While GAAP net income was heavily inflated by the $43.3M SDX sale gain, backing out the one-time asset sales, debt extinguishment losses ($2.8M), derivative losses ($7.2M), and associated tax ($6.9M) reveals a highly profitable core business generating $0.18 per share. This validates the commercial viability of the MIPLYFFA asset.
Stable. Up moderately from $22.8M a year ago. R&D increased by $1.1M due to third-party clinical costs, and SG&A ticked up $1.2M due to professional fees. Non-cash stock compensation accounted for $3.1M. The controlled expense growth combined with 78% YoY top-line growth demonstrates immense operating leverage.
Stable, but consistently immaterial. The product remains a commercial ghost town following the strategic decision in 2025 to scale back sales and marketing efforts. It provides negligible contribution to the top line.
Guidance
Stable. Management reiterated that their $236.8M cash position and positive operating cash flow profile provide sufficient resources to execute strategic priorities without needing to raise equity or debt.
Key Questions
MIPLYFFA Sequential Revenue Decline
MIPLYFFA product revenue declined sequentially from $26.4M to $24.6M despite total enrollments rising. Was this driven by inventory destocking, a gross-to-net adjustment, or changes in patient adherence?
New Patient Acquisition Baseline
With new enrollments returning to 9 in Q1 after the Q4 spike of 24, is 7-10 patients per quarter the appropriate run-rate for the U.S. market moving forward?
DiSCOVER Trial Feasibility
Given the slow pace of the DiSCOVER trial, what specific 'pathways to accelerate clinical development' do you intend to propose to the FDA in H2? Are you seeking to reduce the required number of events?
Capital Allocation Post-Debt
Now that the balance sheet is debt-free and generating operational cash flow, how does management view the potential for external business development to acquire new assets and diversify the pipeline?